Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.

Ava Y Xu Gustavo E VelásquezNan ZhangVincent K ChangPatrick Peter John Phillips Payam NahidSusan E DormanEkaterina V KurbatovaWilliam C WhitworthErin SizemoreKia BryantWendy CarrNicole E BrownMelissa L EngleNguyen Viet NhungPheona NsubugaAndreas H Diacon Kelly E DooleyRichard E ChaissonSusan SwindellsRadojka M Savicnull null

Published in: American journal of respiratory and critical care medicine (2024)

gov, ID: NCT02410772. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keyphrases

pulmonary tuberculosis
mycobacterium tuberculosis
minimally invasive
drug induced
adverse drug
neural network
structure activity relationship
electronic health record